尿液[TIMP-2]·[IGFBP7]指导的急诊科急性肾损伤预防随机对照干预试验
本研究在德国斯图加特Robert-Bosch医院急诊科,对257例患者筛查后纳入100例尿[TIMP-2]·[IGFBP7]>0.3的高危患者,随机分组后干预组立即接受一次性肾内科会诊并实施KDIGO 2012 AKI推荐。主要结局(入院首日中重度AKI发生率)组间无显著差异(P=0.9),但干预组第2天血肌酐更低、第3天尿量有升高趋势(P=0.08),住院期间需RRT者0 vs 3(P=0.09)。结论:目前不推荐在急诊科常规一次性应用该生物标志物指导的KDIGO集束化干预。
要点
- 尿[TIMP-2]·[IGFBP7]>0.3的急诊高危患者中,一次性肾内科会诊未显著降低首日中重度AKI发生率。
- 干预组第2天血肌酐显著更低,最大血肌酐更低,第3天尿量有升高趋势(P=0.08)。
- 干预组住院期间无患者需RRT(0 vs 3,P=0.09),但差异未达统计学显著。
核心结论
- 在急诊科对AKI高危患者一次性常规应用肾内科医生指导的KDIGO集束化干预目前不能推荐。
- 研究终点均呈现一致地倾向于干预组的趋势,值得在更大规模、病情更重的队列中进一步研究。
研究设计与样本
- 前瞻性随机对照干预试验,在德国斯图加特Robert-Bosch医院急诊科进行。
- 筛查257例 eligible 患者,其中100例尿[TIMP-2]·[IGFBP7]>0.3且符合纳入标准者被纳入。
- 干预组随机化后立即接受一次性肾内科会诊并实施KDIGO 2012 AKI推荐。
- 主要结局为入院首日中重度AKI发生率;次要结局包括入院3天内AKI发生、需RRT、住院时长和死亡。
主要发现
- 主要结局在组间无显著差异(P=0.9),入院首日及前3天内均无显著差异。
- 干预组第2天血清肌酐显著更低(P<0.05),最大血清肌酐也更低。
- 干预组第3天尿量有升高趋势(P=0.08)。
- 干预组住院期间无患者需RRT(0 vs 3,P=0.09)。
关键数值与推荐
- 纳入标准包括尿[TIMP-2]·[IGFBP7]>0.3。
- 干预措施为一次性肾内科会诊并实施KDIGO 2012 AKI推荐。
临床怎么用
- 急诊科对AKI高危患者不宜常规一次性应用尿[TIMP-2]·[IGFBP7]指导的KDIGO集束化肾内科会诊干预。
- 生物标志物指导的早期干预策略仍需在更大规模、病情更重的患者中进一步验证。
局限性
- 研究样本量较小(纳入100例),可能不足以检测出临床重要差异。
- 干预为一次性肾内科会诊,未评估重复或持续干预的效果。
- 研究在单中心急诊科进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early detection and prevention of acute kidney injury (AKI) is important to reduce morbidity and mortality. Discovery of early-detection biomarkers has enabled early preventive approaches. There are no data on early biomarker-guided intervention with nephrological consultation in emergency departments (EDs). METHODS: In this prospective randomized controlled intervention trial, patients at high risk for AKI were screened with urinary [TIMP-2]·[IGFBP7] in the ED of Robert-Bosch-Hospital (Stuttgart, Germany). We screened 257 eligible patients of whom 100 met the inclusion criteria, with urinary [TIMP-2]·[IGFBP7] >0.3, and were included. The intervention group received immediate one-time nephrological consultation after randomization, implementing Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations on AKI. The primary outcome was the incidence of moderate to severe AKI within the first day after admission. Secondary outcomes were AKI occurrence within 3 days after admission, need for renal replacement therapy (RRT), length of hospital stay and death. RESULTS: The primary outcome did not differ significantly (P = 0.9) between the groups, neither within the first day nor within the first 3 days after admission. The intervention group had significantly (P < 0.05) lower serum creatinine (SCr) on Day 2 and lower maximum SCr and tended (P = 0.08) to have higher urine output (UOP) at Day 3 than the non-intervention group. No patient in the intervention group needed RRT (0 versus 3) during the hospital stay (P = 0.09). CONCLUSIONS: One-time routine nephrologist-guided application of the KDIGO bundle in ED patients with a risk for AKI cannot currently be recommended. However, due to the uniform trend of study endpoints in favour of intervention, further trials to investigate larger cohorts of more severely ill patients are warranted. TRIAL REGISTRATION: www.ClinicalTrials.gov, study number NCT02730637.
引用
- Schanz M, Wasser C, Allgaeuer S, et al. Urinary [TIMP-2]·[IGFBP7]-guided randomized controlled intervention trial to prevent acute kidney injury in the emergency department. Nephrol Dial Transplant. 2019. PMID: 29961888. doi:10.1093/ndt/gfy186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。